ajax loader

Loading...


Ride-the-Wave Strategy – Best for Stock Traders

Ride-the-Wave targets multi-day price momentum following a company’s earnings announcement (EA). With this strategy:

  1. Buy a stock one day post-EA if a stock reacts positively post-earnings:
    1. Near the close of trading the EA-day for a pre-market-EA
    2. Near the close of the following day for a post-market-EA
  2. Sell-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Similarly,

  1. short a stock one day post-EA if a stock reacts negatively post-earnings:
    1. near the close of trading the EA-day for a premarket-EA
    2. near the close of the following day for a post-market-EA
  2. then buy-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Important: Ride-the-Wave is predicated on significant price momentum triggered by an EA. The 7-10 day scenario is the maximum trade hold-time. If you see post EA-momentum is halted or reversed by a significant opposite move, re-evaluate your presence in the trade.

This popular StockEarnings screen below will give you a list of stocks that historically exhibit significant price momentum following an EA for the next seven days:

  1. Stocks exhibiting positive post-EA price moves are buy-candidates
  2. Stocks exhibiting negative post-EA price moves are sell/short-candidates

The screen includes those stocks whose Earnings just came out in last two days.

Screen criteria:

  1. Earnings Date Start Date : Current Date + -1 Day
  2. Earnings Date End Date : Current Date + -2 Days
  3. Predicted Move (Next Day) Max : 7%
  4. Predicted Move (On 7th Day) Min : 7%

Strategy Guideline:

  1. Buy the stock if stock has reacted positively. Short the stock if stock has reacted negatively (see above).
  2. Close the position in 7-10 days, or possibly earlier based on price move.

Volatility Crush Strategy - Best for Options Traders

The Volatility Crush strategy is used with stocks that typically experience relatively low-to-moderate price moves (≤4%) following their Earnings Announcements (EA). The basic trade idea is to sell put or call options right before the EA, collecting a credit when options premium is very high due to elevated implied volatility (IV). You then close the position right after the EA by buying the option back much cheaper due to the significant drop in IV that occurs after the mystery of the EA disappears. In assessing this trade, you need to do your homework to ensure you collect sufficient premium to make the trade worthwhile.

This trade is practical due to the low-to-moderate price-move after the EA, which generally won’t significantly affect the options price, unlike an “action” stock, which experience great price moves post-EA. With these symbols, if you’re on the right side of the price move, that’s a great thing. But if you’re on the wrong side of the move, not so great. Consequently, by minimizing the effect of the post-EA price move, you have a much better chance to profit from the reduction in IV without it being ruined by a violent price move.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular stockearnings screen will give you a list of stocks which do not react more than 4% fpost-EA. It includes only those stocks whose earnings are releasing next day.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 1
  2. Earnings Date End Date : Current Date + 1
  3. Predicted Move (Next Day) Max : 4%
  4. Options Type: Weekly

Strategy Guideline:

  1. Options Strategy: Sell Call and Put
  2. Options Strike Price: Current Stock Price – (% Predicated Move x 2)
  3. Expiration Date: It should generally be the closest expiry immediately after the EA.
  4. Buy Insurance: Buying back Call and Put at Strike price which 10% lower than Sell Strike Price is optional but recommended.

Watch Video for More Detail

Volatility Rush Strategy - Best for Options Traders

The Volatility Rush takes advantage of increasing options premiums into earnings announcements (EA) caused by an anticipated rise in Implied Volatility (IV). With this strategy, Buy a Call and Put at-the-money (a long straddle) 2-3 weeks before the EA when IV is lower. Sell the position either (1) the night before the EA when the company announces earnings pre-market, or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular screen will give you a list of stocks whose Options premiums tend to rise into Earnings. It includes only those stocks whose Earnings are at least two weeks away from today.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 15 Days
  2. Earnings Date End Date : Current Date + 30 Days
  3. Predicted Move (Next Day) Min : 5%
  4. Options Type: Weekly or Monthly if that lines up with the two to three-week lead-time for entering the trade

Strategy Guideline:

  1. Buy a Straddle at or close to the money two to three weeks pre-EA.
  2. Sell the position either the night before the EA when the company announces earnings pre-market, or during the EA day when it announces post-market.
  3. Expiration date should generally be the closest expiry immediately after the EA.
  4. Straddle price should not be more 60% of predicted move.

Predicted Move (Volatility)

Similar to Implied Volatility in Options. Expected volatility % based on our Proprietary Volatility Predication Model. We are expecting that stock price will likely to reach % in either direction by the end of next trading session after Earnings are released and not necessarily the closing volatility %.

Why is it important?

    This indicator helps

  1. Knowing expected volatility in stocks after Earnings helps to decide trading stocks before Earnings Announcement.
  2. Taking Advantage of volatility collapse following Earnings Results by using Advance Options strategies such as Spread and Straddles.

Since Last Earnings

Change in share price since last Earnings release.

Why is it Important?

When share has gained more than 10% since it's last Earning release, it tends to over react to minor bad news and give up some gains if not all. So, it contains more downside volatility than upside When share has dropped more than 10% since it's last Earning release, it tends to over react to minor good news and recover some drops if not all. So, it contains more upside volatility than downside.

EPS Surprise (%)

Occurs when a company's reported quarterly or annual profits are above or below analysts' expectations. Here is the formula to derive % EPS Surprice:

Actual EPS - Estimated EPS
------------------------------------- x 100
Estimated EPS

Why is it Important?

Earnings surprises can have a huge impact on a company's stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock's price, but also to a gradual increase over time. Hence, it's not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

Next Day Price Change (%)

Next Regular trading session Closing price following Earnings result.

For After Market Close Earnings, It is a next trading day closing price. For Before Market Open Earnings, It is the same trading day closing price.

Why is it Important?

Next Day price change is a reaction of Earnings result.

Outlook Therapeutics Inc. (NASDAQ: OTLK) Expects Q4 2021 EPS Loss of $0.09 per Share

Posted on Dec 21, 2021 by Neha Gupta

Outlook Therapeutics Inc. (NASDAQ: OTLK) Expects Q4 2021 EPS Loss of $0.09 per Share

Outlook Therapeutics Inc. (NASDAQ: OTLK) has confirmed that it will release its Q4 2021 earnings on Wednesday, December 22, 2021.

What to look for

The firm has begun initiatives such as drug substance manufacture with FUJIFILM Diosynth Biotechnology in preparation for the commercial launch of ONS-5010 in 2022. Furthermore, outlook Therapeutics is preparing registration documents for regulatory clearance in Europe via a separate route and will submit them after completing FDA submissions with the US FDA.

Earnings: Stockearning’s estimated EPS for Q4 2021 is expected to be around $0.09 per share. In the third quarter, the company reported a net loss attributable to shareholders of $12.2 million or $0.07 per basic share. For the third quarter of 2021, the company had a net loss of $0.03 per share. Historical EPS Performance shows that the company has in the past 12 quarters beat estimates five times (45%) and missed estimates once (9%).

Revenue: At the end of the third quarter, the company had cash and investments of around $19.7 million. The company's cash is adequate to run its planned operations through December 2021.

Stock movement: Outlook Therapeutics shares have lost 45.1% since the company released Q3 2021 earnings. However, following the earnings release, the company's shares have been UP six times in the last 12 quarters. So, the historical price reaction suggests a 50% probability of the share price going UP once Outlook Therapeutics reports its fiscal Q4 2021 quarterly earnings. According to the Stockearning algorithm, the predicted first-day move is 6%, while the predicted move on the seventh day is 28%.

What analysts are saying

Brookline Capital Markets analyst Kumaraguru Raja raised his price target in Outlook Therapeutics from $5 to $8 but maintained a “Buy” rating. The analyst said, “A new biologics license application (BLA) submission, under the PHSA 351(a) regulatory pathway, for wet AMD is planned in the calendar first quarter of 2022. Outlook is also working on filing for approval in Europe in 2022. We are increasing our estimates and our probability of success to 95%.”

H.C. Wainwright analyst Douglas Tsao reiterated his “buy” rating on the stock but raised his target price for the shares from $5 to $6. Outlook Therapeutics announced exceptional data showing Lytenava's statistically significant superiority over Lucentis in subjects with more than or equal to 15 letters corrected visual acuity and average BCVA score gain in both intent to treat and according to protocol populations per Tsao’s research note to investors. According to the analyst, the 18% response rate differential leaves no doubt about Lytenava's performance. Tsai also raised the drug's chances of being successful in wet macular degeneration to roughly 80%.

Related News

Micron Technology Inc. (NASDAQ:MU) Earnings Expectation, Fiscal Q1 2022 EPS of $2.1

Outlook Therapeutics Inc. (NASDAQ: OTLK) Earnings Expectation, Loss Per Share of $0.09 in Q4 2021

Neha has a passion for understanding the real value of stocks in publicly traded markets. She has a BA in Finance and a Masters in microeconomics. Anne has worked as a consultant advising buy-side firms and long-only equity fund managers. At stocksearning.com, she anchors our fundamental research writing desk.

Join over 100,000 investors who get daily notable Earnings alerts with predicted move.